Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Victor Gordon

Pulmonary Disease Shelby Twp, MI Medical Doctor

NPI 1346553781 CMS profile 287992

50505 Schoenherr Rd Ste 290, Shelby Twp, MI 48315

Open in the dashboard

General payments

$1,976

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victor Gordon of Shelby Twp, MI is reported in the CMS Open Payments database as having received $1,976 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $367 19
2024 General $131 5
2023 General $473 9
2022 General $286 10
2021 General $134 8
2020 General $33 2
2019 General $553 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victor Gordon
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Victor Gordon were reported at $367. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Victor Gordon Pulmonary Disease median Middle half National median
2019 $553 $377 $109–$1,340 $163
2020 $33 $230 $56–$907 $114
2021 $134 $269 $68–$1,072 $132
2022 $286 $390 $100–$1,457 $149
2023 $473 $419 $114–$1,659 $160
2024 $131 $476 $123–$1,818 $164
2025 $367 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Insmed, Inc. $311 8 payments
  2. Pulmonx Corporation $256 4 payments
  3. Jazz Pharmaceuticals Inc. $188 5 payments
  4. AstraZeneca Pharmaceuticals LP $186 13 payments
  5. GlaxoSmithKline, LLC. $182 11 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $149 9 payments
  7. Sunovion Pharmaceuticals Inc. $95 8 payments
  8. Inspire Medical Systems, Inc. $88 1 payment
  9. Harmony Biosciences LLC $73 3 payments
  10. Philips Electronics North America Corporation $72 4 payments
  11. Other $375 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,976 83 payments
Products named General payments · program years 2019–2025
  1. Arikayce $311 8 payments
  2. CHARTIS CATHETER $256 4 payments
  3. ZEPHYR DELIVERY CATHETER $256 4 payments
  4. ZEPHYR ENDOBRONCHIAL VALVE $256 4 payments
  5. PULMONX CHARTIS TABLET CONSOLE $256 4 payments
  6. NUCALA $150 9 payments
  7. SPIRIVA RESPIMAT $132 8 payments
  8. XYREM $122 1 payment
  9. LONHALA MAGNAIR $95 8 payments
  10. INSPIRE $88 1 payment
  11. Other $1,154 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

849

Median for Pulmonary Disease: 936

Drug cost

$336,291

Median for Pulmonary Disease: $487,987

Branded share of claims

78.2%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 261 $229,346
Spiriva Respimat Tiotropium Bromide Brand 61 $39,711
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 23 $17,323
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $11,105
Breo Ellipta Fluticasone/Vilanterol Brand 13 $6,588
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 36 $6,507
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 15 $6,431
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 18 $5,506
Ventolin Hfa Albuterol Sulfate Brand 69 $4,777
Albuterol Sulfate Hfa Albuterol Sulfate Brand 129 $4,234

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$147,281

Medicare's payments for the services billed

Medicare patients

654

Average age 74

Services billed

1,988

384 women, 270 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 61%
Ischemic heart disease 57%
Arthritis 55%
Heart failure 46%
Diabetes 44%
Atrial fibrillation 41%
Chronic kidney disease 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $21
$21 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $18
$18 261 —
AREXVY
  • GlaxoSmithKline, LLC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record